1
|
Marshall Cavendish Corporation: Mammal
anatomy: An illustrated guide. Cavendish Square Publishing. NY:
2010.
|
2
|
Gill J, Ahluwalia MK, Geller D and Gorlick
R: New targets and approaches in osteosarcoma. Pharmacol Ther.
137:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Errani C, Longhi A, Rossi G, Rimondi E,
Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, et
al: Palliative therapy for osteosarcoma. Expert Rev Anticancer
Ther. 11:217–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Meyers PA, Heller G, Healey J, Huvos A,
Lane J, Marcove R, Applewhite A, Vlamis V and Rosen G: Chemotherapy
for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering
experience. J Clin Oncol. 10:5–15. 1992.PubMed/NCBI
|
5
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W,
Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized,
prospective trial of the addition of ifosfamide and/or muramyl
tripeptide to cisplatin, doxorubicin and high-dose methotrexate. J
Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
PosthumaDeBoer J, Witlox M, Kaspers G and
Van Royen B: Molecular alterations as target for therapy in
metastatic osteosarcoma: A review of literature. Clin Exp
Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Brun J, Dieudonné FX, Marty C, Müller J,
Schüle R, Patiño-García A, Lecanda F, Fromigué O and Marie PJ: FHL2
silencing reduces Wnt signaling and osteosarcoma tumorigenesis in
vitro and in vivo. PloS One. 8:e550342013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Patiño-García A, Piñeiro ES, Díez MZ,
Iturriagagoitia LG, Klüssmann FA and Ariznabarreta LS: Genetic and
epigenetic alterations of the cell cycle regulators and tumor
suppressor genes in pediatric osteosarcomas. J Pediatr Hematol
Oncol. 25:362–367. 2003. View Article : Google Scholar : PubMed/NCBI
|
9
|
Tsuchiya T, Sekine K, Hinohara S, Namiki
T, Nobori T and Kaneko Y: Analysis of the p16INK4, p14ARF, p15,
TP53 and MDM2 genes and their prognostic implications in
osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 120:91–98.
2000. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wadayama B, Toguchida J, Shimizu T,
Ishizaki K, Sasaki MS, Kotoura Y and Yamamuro T: Mutation spectrum
of the retinoblastoma gene in osteosarcomas. Cancer Res.
54:3042–3048. 1994.PubMed/NCBI
|
11
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
X and Hoang BH: The Wnt signaling pathway: Implications for therapy
in osteosarcoma. 2011.
|
12
|
Boland JM, Kwon ED, Harrington SM,
Wampfler JA, Tang H, Yang P and Aubry MC: Tumor B7-H1 and B7-H3
expression in squamous cell carcinoma of the lung. Clinical Lung
Cancer. 14:157–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Arigami T, Uenosono Y, Hirata M, Yanagita
S, Ishigami S and Natsugoe S: B7-H3 expression in gastric cancer: A
novel molecular blood marker for detecting circulating tumor cells.
Cancer Sci. 102:1019–1024. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Arigami T, Narita N, Mizuno R, Nguyen L,
Ye X, Chung A, Giuliano AE and Hoon DS: B7-H3 ligand expression by
primary breast cancer and associated with regional nodal
metastasis. Ann Surg. 252:1044–1051. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zang X, Thompson RH, Al-Ahmadie HA, Serio
AM, Reuter VE, Eastham JA, Scardino PT, Sharma P and Allison JP:
B7-H3 and B7x are highly expressed in human prostate cancer and
associated with disease spread and poor outcome. Proc Natl Acad
Sci. 104:19458–19463. 2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wang L, Zhang Q, Chen W, Shan B, Ding Y,
Zhang G, Cao N, Liu L and Zhang Y: B7-H3 is overexpressed in
patients suffering osteosarcoma and associated with tumor
aggressiveness and metastasis. PloS One. 8:e706892013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Khanna C, Prehn J, Yeung C, Caylor J,
Tsokos M and Helman L: An orthotopic model of murine osteosarcoma
with clonally related variants differing in pulmonary metastatic
potential. Clin Exp Metastasis. 18:261–271. 2000. View Article : Google Scholar : PubMed/NCBI
|
18
|
Hamidouche Z, Haÿ E, Vaudin P, Charbord P,
Schüle R, Marie PJ and Fromigué O: FHL2 mediates
dexamethasone-induced mesenchymal cell differentiation into
osteoblasts by activating Wnt/β-catenin signaling-dependent Runx2
expression. FASEB J. 22:3813–3822. 2008. View Article : Google Scholar : PubMed/NCBI
|
19
|
Yang HY, Chu M, Zheng LW, Zwahlen RA, Luo
J, Zou DH and Sun ST: Transgenic B7-H3 therapy induces
tumor-specific immune response in human oral squamous cell cancer:
An in vitro study. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 106:721–728. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Xu YH, Zhang GB, Wang JM and Hu HC: B7-H3
and CD133 expression in non-small cell lung cancer and correlation
with clinicopathologic factors and prognosis. Saudi Med J.
31:980–986. 2010.PubMed/NCBI
|
21
|
Yuan H, Wei X, Zhang G, Li C, Zhang X and
Hou J: B7-H3 over expression in prostate cancer promotes tumor cell
progression. J Urol. 186:1093–1099. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ahmed BA: Awareness and practice of breast
cancer and breast-self examination among university students in
Yemen. Asian Pac J Cancer Prev. 11:101–105. 2009.
|
23
|
Biglarian A, Hajizadeh E, Kazemnejad A and
Zayeri F: Determining of prognostic factors in gastric cancer
patients using artificial neural networks. Asian Pac J Cancer Prev.
11:533–536. 2010.PubMed/NCBI
|
24
|
Nygren M, Tekle C, Ingebrigtsen V and
Fodstad O: B7-H3 and its relevance in cancer; immunological and
non-immunological perspectives. Front Biosci (Elite Ed). 3:989–993.
2010.
|
25
|
Lu P, Liu R, Ma EM, Yang TJ and Liu JL:
Functional analysis of B7-H3 in colonic carcinoma cells. Asian Pac
J Cancer Prev. 13:3899–3903. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Tinkey PT, Lembo TM, Evans GR, Cundiff JH,
Gray KN and Price RE: Postirradiation sarcomas in Sprague-Dawley
rats. Radiat Res. 149:401–404. 1998. View
Article : Google Scholar : PubMed/NCBI
|